June 29, 2020 - Events
Lead therapeutic candidate MOv18 IgE is the world’s first IgE drug to enter clinical trials. Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, hosted a Key Opinion Leader (KOL) webinar for the...
June 24, 2020 - Press Releases
Lead therapeutic candidate MOv18 IgE is the world’s first IgE drug to enter clinical trials Live webinar and conference call on Monday June 29th @ 11am ET / 4pm BST London, June 23, 2020 – Epsilogen, a global leader in the...
June 5, 2020 - Articles
Epsilogen: co-opting IgE antibodies against cancer Epsilogen Ltd was profiled in BioCentury’s Emerging Company Profile on June 5, 2020. See the article in full here
